Table 1 Patients and treatment characteristics for the two groups
3DCRT | VMAT | |||
|---|---|---|---|---|
Number | Percent | Number | Percent | |
Total | 167 | 49 | 174 | 51 |
Gender | ||||
Female | 57 | 34 | 67 | 38.5 |
Male | 110 | 66 | 107 | 61.5 |
Median Age | 53 yrs (range 20–82 yrs) | 54 yrs (range 19–82 yrs) | ||
Karnosky Performance Status (KPS) | ||||
60 | 6 | 3 | 3 | 2 |
70 | 26 | 16 | 25 | 14 |
80 | 68 | 41 | 52 | 30 |
90 | 44 | 26 | 52 | 30 |
100 | 23 | 14 | 42 | 24 |
Histology | ||||
Glioblastoma (GBM) | 129 | 77 | 122 | 70 |
Anaplastic Astrocytoma (AA) | 20 | 12 | 29 | 17 |
Anaplastic Oligoastrocytoma (AOA) | 9 | 5.5 | 10 | 6 |
Anaplastic Oligodendroglioma (AO) | 9 | 5.5 | 13 | 7 |
Isocitrate dehydrogenase (IDH) mutation status | ||||
Wild type | – | – | 126 | 72 |
Mutated | – | – | 38 | 22 |
NA (not available) | 167 | 100 | 10 | 6 |
1p19q codelation | ||||
Codeleted | 18 | 11 | 30 | 17 |
Non codeleted | 20 | 12 | 22 | 13 |
NE (not evaluated for GBM pts) | 129 | 77 | 122 | 70 |
O-6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status | ||||
Methylated | 94 | 54 | 107 | 61 |
Unmethylated | 76 | 46 | 67 | 49 |
Surgery | ||||
Biopsy (B) | 47 | 28 | 22 | 13 |
Partial Resection (PR) | 58 | 35 | 58 | 33 |
Subtotal Resection (SR) | 15 | 9 | 26 | 15 |
Complete Resection (CR) | 47 | 28 | 68 | 39 |
Adjuvant treatment | ||||
RT + concomitant CHT+ adjuvant CHT (TMZ) | 167 | 100 | 174 | 100 |